Literature DB >> 16015369

A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo.

I Cantón1, S Akhtar, N G Gavalas, D J Gawkrodger, A Blomhoff, P F Watson, A P Weetman, E H Kemp.   

Abstract

Vitiligo is an acquired hypomelanotic skin disorder resulting from the loss of functional melanocytes from the cutaneous epidermis and autoimmunity has been suggested to play a part in its pathogenesis. Recently, the missense R620W polymorphism in the PTPN22 gene, which encodes lymphoid protein tyrosine phosphatase (LYP), has been associated with susceptibility to autoimmune disorders. The objective of this study was to ascertain if the disease-associated 1858T allele was also associated with generalised (nonsegmental) vitiligo and so the frequencies of the PTPN22 1858C/T alleles were investigated in 165 English patients with generalised vitiligo and 304 ethnically matched control subjects. The results indicated that the 1858T allele was significantly over-represented in the vitiligo patient group compared with the control cohort. Of 330 vitiligo alleles, 48 (14.5%) encoded the Trp620 variant compared to 52 of 608 (8.6%) control alleles (P=0.006; odds ratio=1.82, 95% confidence interval=1.17-2.82). The results indicate that the LYP missense R620W polymorphism may have an influence on the development of generalised vitiligo and provide further evidence for autoimmunity as an aetiological factor with respect to this disease. Genes and Immunity (2005) 6, 584-587. doi:10.1038/sj.gene.6364243; published online 14 July 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015369     DOI: 10.1038/sj.gene.6364243

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  29 in total

Review 1.  Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease.

Authors:  Richard A Spritz
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

Review 2.  Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases.

Authors:  Stephanie M Stanford; Tomas M Mustelin; Nunzio Bottini
Journal:  Semin Immunopathol       Date:  2010-03-04       Impact factor: 9.623

Review 3.  Genetics of Vitiligo.

Authors:  Richard A Spritz; Genevieve H L Andersen
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

4.  Update on the genetics characterization of vitiligo.

Authors:  Hani A Al-Shobaili
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

5.  Clinical characteristics and PTPN22 1858C/T variant analysis in Jordanian Arab vitiligo patients.

Authors:  Asem Alkhateeb; Firas Qarqaz; Jude Al-Sabah; Tasnim Al Rashaideh
Journal:  Mol Diagn Ther       Date:  2010-06-01       Impact factor: 4.074

Review 6.  Genes and Sjögren's syndrome.

Authors:  Beth L Cobb; Christopher J Lessard; John B Harley; Kathy L Moser
Journal:  Rheum Dis Clin North Am       Date:  2008-11       Impact factor: 2.670

7.  A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.

Authors:  Yantao He; Sijiu Liu; Ambili Menon; Stephanie Stanford; Emmanuel Oppong; Andrea M Gunawan; Li Wu; Dennis J Wu; Amy M Barrios; Nunzio Bottini; Andrew C B Cato; Zhong-Yin Zhang
Journal:  J Med Chem       Date:  2013-06-06       Impact factor: 7.446

Review 8.  Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease.

Authors:  Nunzio Bottini; Erik J Peterson
Journal:  Annu Rev Immunol       Date:  2013-12-18       Impact factor: 28.527

Review 9.  Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity.

Authors:  Stephanie M Stanford; Novella Rapini; Nunzio Bottini
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

10.  The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis.

Authors:  Gwan Gyu Song; Jae-Hoon Kim; Young Ho Lee
Journal:  Mol Biol Rep       Date:  2012-12-24       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.